“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

07 May 2019
Pharma

Visiongain has launched a new pharma report mRNA Vaccines and Therapeutics Market Forecast 2019-2029: Standardized Therapeutic Cancer mRNA Vaccines, Individualized Therapeutic Cancer mRNA Vaccines, Therapeutic Infectious Disease mRNA Vaccines, mRNA Therapeutic for Other Diseases, Bioengineered Vaccine, Gene Transcription, Monoclonal Antibody, Gene Therapy, Cell Therapy.

mRNA-based drugs have emerged as a highly attractive new class of biologics that encodes any protein of interest directly in vivo. The last two decades have been crucial in generating interest in various RNA based technologies. Clinical and preclinical trials in the field have led to positive responses facilitating increasing funding and investment by major pharmaceutical and biopharmaceutical companies. Clinical trials have proven that mRNA vaccines provide long lasting immune responses and are safe in animal and human models.

The lead analyst of the report commented "The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

Effective and safe delivery remains a major challenge despite the potential of RNA therapy. High cost of development and stringent process of regulatory approvals might also restrain the mRNA vaccines and therapeutics market."

Leading companies featured in the report include Argos Therapeutics, Inc., BioNTech AG. CureVac AG, eTheRNA Immunotherapies, ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sangamo Therapeutics, Inc., Tiba Biotech, Translate Bio, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read